Reactions of 3‐benzylindole‐2‐carbohydrazides: Synthesis of new 10‐Benzyl‐1,2‐dihydro‐1‐oxo‐1,2,4‐triazino[4,5‐a]indoles and 3‐Benzyl‐2‐(1,3,4‐oxadiazol‐2‐yl)indoles

3‐Benzylindole‐2‐carbohydrazides (4) on reaction with triethylorthoformate in a polar solvent like DMF yielded only 10‐benzyl‐1,2‐dihydro‐1‐oxo‐1,2,4‐triazino[4,5‐a]indoles (5) while (4) on reaction with triethylorthoacetate in DMF yielded both 10‐benzyl‐4‐methyl‐1,2‐dihydro‐1‐oxo‐1,2,4‐triazino[4,5‐a]indoles (5) and 3‐benzyl‐2‐(5‐methyl‐1,3,4‐oxadiazol‐2‐yl)indoles (6) instead of only the triazinoindoles as expected. The oxadiazolylindoles (6) were also synthesized by refluxing (4) with excess of orthoesters. The structures of the compounds formed were characterized by their analytical and spectral data.     

3/4‐phenylene bisheterocycles from ring transformation reaction of sydnone derivatives: Synthesis of 3‐[3/4‐heterocyclyl]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones from 3/4‐acetylphenylsydnones and their biological properties

The bifunctional 3/4‐[acetyl]phenylsydnones 1a, 1b were subjected to a one‐pot ring conversion to 3‐[3/4‐acetyl]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 2a, 2b , which on further bromination yielded the 3‐[3/4‐bromoacyl]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 3a, 3b . Reaction of these compounds with thiourea yielded the 3‐[3/4‐(2‐aminothiazol‐4‐yl)]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 4a, 4b . The other thiazole derivatives 5a, 5b–7a, 7b were prepared by using thiosemicarbazide, thioacetamide, and thiobenzamide, respectively. In another reaction of the bromoacetyl compounds ( 3a, 3b ) with 2‐aminopyridine and 2‐aminothiazole, the fused biheterocyclic compounds 3‐[3/4‐imidazo‐[1,2‐a]pyridine‐2‐yl]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 8a, 8b and 3‐[3/4‐imidazo‐[2,1‐b]‐thiazol‐6‐yl]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 9a, 9b were obtained. The 3‐[3/4‐(benzofuran‐2‐carbonyl)]phenyl‐5‐methyl‐3H‐[1,3,4]‐oxadiazol‐2‐ones 10a, 10b were obtained by treatment of compounds 3a, 3b with o‐hydroxy benzaldehyde. Most of these compounds exhibited antifungal activity greater than the reference drugs used. © 2007 Wiley Periodicals, Inc. Heteroatom Chem 18:50–54, 2007; Published online in Wiley InterScience ( www.interscience.wiley.com ). DOI 10.1002/hc.20255     

Heterocyclic synthesis: A convenient route to some 2‐mercepto 1,3,4‐oxadiazole and green chemistry microwave‐induced one‐pot synthesis of 2‐aryl 1,3,4‐oxadiazole in quinazolone and their antibacterial and antifungal activity

Several 6‐substituted‐3‐[(5‐mercepto‐1,3,4‐oxadiazol‐2‐yl)methyl]‐2‐substituted quinazolin‐4(3H)‐one or 6‐substituted‐3‐[4‐(5‐mercepto‐1,3,4‐oxadiazol‐2‐yl)phenyl]‐2‐substituedquinazolin‐4(3H)‐one 2(a‐l) and 6‐substituted‐3‐[(5‐phenyl‐1,3,4‐oxadiazol‐2‐yl)methyl]‐2‐substitutedquinazolin‐4(3H)‐one or 6‐substi‐tuted‐3‐[4‐(5‐phenyl‐1,3,4‐oxadiazol‐2‐yl) phenyl]‐2‐substitutedquinazolin‐4(3H)‐one 3(a‐l) were synthesized using conventional and microwave techniques respectively and were screened for antibacterial and antifungal activity.     

Synthesis and Structure of Novel Thieno[2, 3‐d]Pyrimidine Derivatives Containing 1, 3, 4‐Oxadiazole Moiety

The reaction of 5‐(1‐pyrrolyl)‐4‐methyl‐2‐phenylthieno[2, 3‐d]pyrimidine carbohydrazide 5 with CS₂ in the presence of pyridine afforded the 6‐(2, 3‐dihydro‐2‐mercapto‐1, 3, 4‐oxadiazol‐5‐yl)‐4‐methyl‐5‐(1‐pyrrolyl)‐2‐phenylthieno[2, 3‐d]pyrimidine 6 , which reacted with methyl iodide in the presence of sodium methoxide to yield the 6‐(2‐methylthio‐1, 3, 4‐oxadiazol‐5‐yl)‐4‐methyl‐5‐(1‐pyrrolyl)‐2‐phenyl‐thieno[2, 3‐d]pyrimidine 7. The 6‐(2‐substituted‐1, 3, 4‐oxadiazol‐5‐yl)‐2‐phenylthieno[2, 3‐d]pyrimidine derivatives 9, 11 and 13 were obtained by the condensation of 6‐(2‐methylthio‐1, 3, 4‐oxadiazol‐5‐yl)‐2‐phenylthieno[2, 3‐d]pyrimidine 7 with appropriate secondary amines. The structure of the new compounds was substantiated from their IR, UV‐vis spectroscopy, ¹H NMR, mass spectra, elemental analysis and X‐ray crystal analysis.     

Synthesis and Characterization of New 7‐Substituted 6,14‐Ethenomorphinane Derivatives: N‐{5‐[(5α,7α)‐4,5‐Epoxy‐3,6‐dimethoxy‐17‐methyl‐6,14‐ethenomorphinan‐7‐yl]‐1,3,4‐oxadiazol‐2‐yl}arenamines

In this study, (5α,7α)‐4,5‐epoxy‐3,6‐dimethoxy‐17‐methyl‐6,14‐ethenomorphinan‐7‐carboxylic acid hydrazide ( 5 ) was synthesized by the condensation of methyl (5α,7α)‐4,5‐epoxy‐3,6‐dimethoxy‐17‐methyl‐6,14‐ethenomorphinan‐7‐carboxylate ( 4 ) with NH₂NH₂⋅H₂O. The (5α,7α)‐4,5‐epoxy‐3,6‐dimethoxy‐17‐methyl‐6,14‐ethenomorphinan‐7‐carboxylic acid 2‐[(arylamino)carbonyl]hydrazides 6a – 6q were prepared by the reaction of 5 with corresponding substituted aryl isocyanates, and the N‐{5‐[(5α,7α)‐4,5‐epoxy‐3,6‐dimethoxy‐17‐methyl‐6,14‐ethenomorphinan‐7‐yl]‐1,3,4‐oxadiazol‐2‐yl}arenamines 7a – 7q were obtained via the cyclization reaction of 6a – 6q in the presence of POCl₃. The synthesized compounds have a rigid morphine structure, including the 6,14‐endo‐etheno bridge and the 5‐(arylamino)‐1,3,4‐oxadiazol‐2‐yl residue at C(7) adopting the (S)‐configuration (7α). The structures of the compounds were confirmed by high‐resolution mass spectrometry (HR‐MS) and various spectroscopic methods such as FT‐IR, ¹H‐NMR, ¹³C‐NMR, APT, and 2D‐NMR (HETCOR, COSY, INADEQUATE).     

Syntheses of New Unsymmetrical 2,5‐Disubstituted‐1,3,4‐oxadiazoles and 1,2,4‐Triazolo[3,4‐b]‐1,3,4‐thiadiazoles Bearing Thieno[2,3‐c]pyrazolo Moiety

New series of (thieno[2,3‐c]pyrazolo‐5‐yl)‐[1,2,4]triazolo[3,4‐b][1,3,4]thiadiazoles 10a , 10b , 10c and (thieno[2,3‐c]pyrazol‐5‐yl)‐1,3,4‐oxadiazol‐3(2H)‐yl)ethanones 6a , 6b , 6c has been synthesized from thieno[2,3‐c]pyrazole‐5‐carbohydrazide 3 by multistep reaction sequence. (5‐Aryl‐1,3,4‐oxadiazol‐2‐yl)‐1H‐thieno[2,3‐c]pyrazoles 4a , 4b , 4c were also synthesized from thieno[2,3‐c]pyrazole‐5‐carbohydrazide 3 by cyclization with various aromatic carboxylic acids. The hydrazide 3 was obtained by reaction of thieno[2,3‐c]pyrazole‐5‐carboxylate 2 with hydrazine hydrate in good yield, and compound 2 was obtained by the reaction of 5‐chloro‐3‐methyl‐1‐phenyl‐1H‐pyrazole‐4‐carbaldehyde 1 and 2‐ethyl thioglycolate in presence of sodium alcoholate in good yield.     

Synthesis of 1,3,4‐Oxadiazole Acyclo C‐Nucleosides Bearing 5‐Methylthio{7‐substituted‐1,2,4‐triazolo[1,5‐d]tetrazol‐6‐yl}moieties

Oxidative cyclization of the sugar hydrazones ( 3_a‐f ) derived from {7H‐1,2,4‐triazolo[1,5‐d]tetrazol‐6‐ylsulfanyl}acetic acid hydrazide ( 1 ) and aldopentoses 2_a‐c or aldohexoses 2_d‐f with bromine in acetic acid in the presence of anhydrous sodium acetate, followed by acetylation with acetic anhydride gave the corresponding 2‐(per‐O‐acetyl‐alditol‐l‐yl)‐5‐methylthio{7H‐1,2,4‐triazolo[1,5‐d]tetrazol‐6‐yl}‐1,3,4‐oxadiazoles ( 5_a‐f ). Condensative cyclization of the sugar hydrazones ( 3_a‐f ) by heating with acetic anhydride gave the corresponding 3‐acetyl‐2‐(per‐O‐acetyl‐alditol‐1‐yl)‐2,3‐dihydro‐5‐methylthio{7‐acetyl‐1,2,4‐triazolo[1,5‐d]tetrazol‐6‐yl}‐1,3,4‐oxadiazoles ( 11_a‐f ). De‐O‐acetylation of the acyclo C‐nucleoside peracetates ( 5 and 11 ) with methanolic ammonia afforded the hydrazono lactones ( 7 ) and the acyclo C‐nucleosides ( 12 ), respectively. The structures of new oxadiazole derivatives were confirmed by analytical and spectral data.     

Microwave‐assisted Synthesis of 6‐{(5‐Aryl‐1,3,4‐oxadiazol‐2‐yl)methyl}‐6H‐indolo[2,3‐b]quinoxalines

An efficient and convenient synthesis of a new series of 2‐{(6H‐indolo[2,3‐b]quinoxalin‐6‐yl)methyl}‐5‐aryl‐1,3,4‐oxadiazoles from readily available 1,2‐diaminobenzene and isatins under microwave irradiation conditions was disclosed. The 6‐{(5‐aryl‐1,3,4‐oxadiazol‐2‐yl)methyl}‐6H‐indolo[2,3‐b]quinoxalines were also prepared by the thermal cyclo‐condensation reaction of 2‐(6H‐indolo[2,3‐b]quinoxalin‐6‐yl)acetohydrazides with carboxylic acids in refluxing POCl₃. The microwave‐assisted synthesis was rapid and resulted in higher yield of the products at lower operating temperature with reduced waste generation in comparison with the thermal reaction protocol.     

Polycyclic N‐Heterocyclic Compounds. Part 78: Synthesis of N‐[2‐([1,2,4]Oxadiazol‐5‐yl)cyclohepten‐1‐yl]formamide Oximes and Their Evaluation as Inhibitors of Platelet Aggregation

N‐[2‐([1,2,4]Oxadiazol‐5‐yl)cyclohepten‐1‐yl]formamide oximes were synthesized by fusion of (6,7,8,9‐tetrahydro‐5H‐cyclohepta[1,2‐d]pyrimidin‐4‐yl)amidines with hydroxylamine hydrochloride through a subsequent rearrangement reaction. Effects of the products as well as the structurally related N‐[4‐([1,2,4]oxadiazol‐5‐yl)‐2,3‐dihydro[1]benzoxepin‐5‐yl]formamide oximes and N‐[4‐([1,2,4]oxadiazol‐5‐yl)‐2,3‐dihydro[1]benzothiepin‐5‐yl]formamide oximes on platelet aggregation were evaluated.     

Polymorphism of 3‐(5‐phenyl‐1,3,4‐oxadiazol‐2‐yl)‐ and 3‐[5‐(pyridin‐4‐yl)‐1,3,4‐oxadiazol‐2‐yl]‐2H‐chromen‐2‐ones

This study of 3‐(5‐phenyl‐1,3,4‐oxadiazol‐2‐yl)‐2H‐chromen‐2‐one, C₁₇H₁₀N₂O₃, 1 , and 3‐[5‐(pyridin‐4‐yl)‐1,3,4‐oxadiazol‐2‐yl]‐2H‐chromen‐2‐one, C₁₆H₉N₃O₃, 2 , was performed on the assumption of the potential anticancer activity of the compounds. Three polymorphic structures for 1 and two polymorphic structures for 2 have been studied thoroughly. The strongest intermolecular interaction is stacking of the `head‐to‐head' type in all the studied crystals. The polymorphic structures of 1 differ with respect to the intermolecular interactions between stacked columns. Two of the polymorphs have a columnar or double columnar type of crystal organization, while the third polymorphic structure can be classified as columnar‐layered. The difference between the two structures of 2 is less pronounced. Both crystals can be considered as having very similar arrangements of neighbouring columns. The formation of polymorphic modifications is caused by a subtle balance of very weak intermolecular interactions and packing differences can be identified only using an analysis based on a study of the pairwise interaction energies.     

New Pyrazolyl‐Nicotinic Acids,Methyl Esters,and 1,3,4‐Oxadiazolyl‐pyrazolyl‐pyridine Tricyclic Scaffold Derivatives from 6‐Hydrazinylnicotinic Acid Hydrazide Hydrate

This paper describes an efficient approach for the synthesis of a new series of 6‐[3‐alkyl(aryl/heteroaryl)‐5‐trifluoromethyl‐1H‐pyrazol‐1‐yl]nicotinic acids (where alkyl = CH₃; aryl = Ph, 4‐OCH₃Ph, 4,4′‐BiPh; and heteroaryl = 2‐Furyl) from the hydrolysis reaction of alkyl(aryl/heteroaryl)substituted 2‐(5‐trifluoromethyl‐5‐hydroxy‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)‐5‐(5‐trifluoromethyl‐5‐hydroxy‐4,5‐dihydro‐1H‐1‐carbonylpyrazol‐1‐yl)pyridines, under basic conditions and at 70–95% yields. In a subsequent step, the esterification reaction of pyrazolyl‐nicotinic acids done in thionyl chloride and methanol led to the isolation of a series of methyl 6‐[alkyl(aryl/heteroaryl)‐5‐trifluoromethyl‐1H‐pyrazol‐1‐yl] nicotinates as stable hydrochloride salts at 64–84% yields, which could be easily converted to hydrazides to give new oxadiazolyl‐pyrazolyl‐pyridine tricyclic scaffolds at good yields from a [4 + 1] cyclocondensation reaction with 1,1,1‐triethoxyethane and 1‐(triethoxymethyl)benzene as the reagent/solvent.     

Synthesis of Some 7H‐s‐Triazolo[3,4‐b]‐1,3,4‐thiadiazine Derivatives

The cyclization of 1‐amino‐2‐mercapto‐5‐[5‐methyl‐1‐(4‐methylphenyl)‐1,2,3‐triazol‐4‐yl]‐1,3,4‐triazole with various α‐haloketone in absolute ethanol yields 7H‐3‐[5‐methyl‐1‐(4‐methylphenyl)‐1,2,3‐triazol‐4‐yl]‐6‐substituted‐s‐triazolo[3,4‐b]‐1,3,4‐thiadiazines and their structures are established by elemental analysis, MS, IR and ¹H NMR spectral data.     

The coordination chemistry of two symmetric double‐armed oxadiazole‐bridged organic ligands with copper salts

Two new symmetric double‐armed oxadiazole‐bridged ligands, 4‐methyl‐{5‐[5‐methyl‐2‐(pyridin‐3‐ylcarbonyloxy)phenyl]‐1,3,4‐oxadiazol‐2‐yl}phenyl pyridine‐3‐carboxylate (L1) and 4‐methyl‐{5‐[5‐methyl‐2‐(pyridin‐4‐ylcarbonyloxy)phenyl]‐1,3,4‐oxadiazol‐2‐yl}phenyl pyridine‐4‐carboxylate (L2), were prepared by the reaction of 2,5‐bis(2‐hydroxy‐5‐methylphenyl)‐1,3,4‐oxadiazole with nicotinoyl chloride and isonicotinoyl chloride, respectively. Ligand L1 can be used as an organic clip to bind Cu^II cations and generate a molecular complex, bis(4‐methyl‐{5‐[5‐methyl‐2‐(pyridin‐3‐ylcarbonyloxy)phenyl]‐1,3,4‐oxadiazol‐2‐yl}phenyl pyridine‐3‐carboxylate)bis(perchlorato)copper(II), [Cu(ClO₄)₂(C₂₈H₂₀N₄O₅)₂], (I). In compound (I), the Cu^II cation is located on an inversion centre and is hexacoordinated in a distorted octahedral geometry, with the pyridine N atoms of two L1 ligands in the equatorial positions and two weakly coordinating perchlorate counter‐ions in the axial positions. The two arms of the L1 ligands bend inward and converge at the Cu^II coordination point to give rise to a spirometallocycle. Ligand L2 binds Cu^I cations to generate a supramolecule, diacetonitriledi‐μ₃‐iodido‐di‐μ₂‐iodido‐bis(4‐methyl‐{5‐[5‐methyl‐2‐(pyridin‐4‐ylcarbonyloxy)phenyl]‐1,3,4‐oxadiazol‐2‐yl}phenyl pyridine‐4‐carboxylate)tetracopper(I), [Cu₄I₄(CH₃CN)₂(C₂₈H₂₀N₄O₅)₂], (II). The asymmetric unit of (II) indicates that it contains two Cu^I atoms, one L2 ligand, one acetonitrile ligand and two iodide ligands. Both of the Cu^I atoms are four‐coordinated in an approximately tetrahedral environment. The molecule is centrosymmetric and the four I atoms and four Cu^I atoms form a rope‐ladder‐type [Cu₄I₄] unit. Discrete units are linked into one‐dimensional chains through π–π interactions.     

A new two‐dimensional ZnII coordination polymer based on 1,3‐bis(2‐methyl‐1H‐imidazol‐1‐yl)benzene and 5‐nitrobenzene‐1,3‐dicarboxylic acid: synthesis,crystal structure and physical properties

A novel two‐dimensional (2D) Zn^II coordination framework, poly[[μ‐1,3‐bis(2‐methyl‐1H‐imidazol‐1‐yl)benzene](μ‐5‐nitrobenzene‐1,3‐dicarboxylato)zinc(II)], [Zn(C₈H₃NO₆)(C₁₄H₁₄N₄)]_n or [Zn(NO₂‐BDC)(1,3‐BMIB)]_n [1,3‐BMIB is 1,3‐bis(2‐methyl‐1H‐imidazol‐1‐yl)benzene and NO₂‐H₂BDC is 5‐nitrobenzene‐1,3‐dicarboxylic acid], has been prepared and characterized by IR, elemental analysis, thermal analysis and single‐crystal X‐ray diffraction. Single‐crystal X‐ray diffraction analysis revealed that the compound is a new 2D polymer with a 6³ topology parallel to the (10) crystal planes based on left‐handed helices, right‐handed helical NO₂‐BDC–Zn chains and [Zn₂(1,3‐BMIB)₂]_n clusters. In the crystal, adjacent layers are further connected by C—H…O hydrogen bonds, C—H…π interactions, C—O…π interactions and N—O…π interactions to form a three‐dimensional structure in the solid state. In addition, the compound exhibits strong fluorescence emissions in the solid state at room temperature.     

Synthesis of 3‐[5‐methyl‐1‐(4‐methylphenyl)‐1,2,3‐triazol‐4‐yl]‐6‐substituted‐s‐triazolo[3,4‐b]‐1,3,4‐thiadiazoles

Several 3‐[5‐methyl‐1‐(4‐methylphenyl)‐1,2,3‐triazol‐4‐yl]‐6‐substituted‐1,3,4‐triazolo[3,4‐b]‐1,3,4‐thiadiazoles have been synthesized and the structures of these compounds were established by elemental analysis, MS, IR and ¹H NMR spectral data.     

In(OTf)3催化下水相合成2-(3,4,5-三甲氧基苯基)-5-[(5-烷硫基-1,3,4-噁二唑-2-基)硫甲基]-1,3,4-噻二唑类衍生物

以2-巯基-5-(3,4,5-三甲氧基苯基)-1,3,4-噻二唑为原料,经醚化、酰肼化、闭环、硫醚化四步反应合成了10个2-(3,4,5-三甲氧基苯基)-5-[(5-烷硫基-1,3,4-噁二唑-2-基)硫甲基]- 1,3,4-噻二唑类衍生物。通过元素分析、IR、MS、1H NMR和 13C NMR对目标化合物进行了表征。采用In(OTf)3催化下40 oC水相合成目标化合物,具有反应条件温和、合成收率高、催化剂可循环使用等特点。     

Syntheses and structures of one CuI‐containing coordination polymer and two macrocyclic supramolecular complexes based on flexible 1,3,4‐oxadiazole‐containing ligands

Three coordination complexes with Cu^I centres have been prepared using the symmetrical flexible organic ligands 1,3‐bis{[5‐(quinolin‐2‐yl)‐1,3,4‐oxadiazol‐2‐yl]sulfanyl}propane (L1) and 1,4‐bis{[5‐(quinolin‐2‐yl)‐1,3,4‐oxadiazol‐2‐yl]sulfanyl}butane (L2). Crystallization of L1 with Cu(SO₃CF₃)₂ and of L2 with Cu(BF₄)₂ and Cu(ClO₄)₂ in a CH₂Cl₂/CH₃OH mixed‐solvent system at room temperature afforded the coordination complexes catena‐poly[[copper(I)‐μ‐1,3‐bis{[5‐(quinolin‐2‐yl)‐1,3,4‐oxadiazol‐2‐yl]sulfanyl}propane] methanesulfonate dichloromethane 0.6‐solvate], {[Cu(C₂₅H₁₈N₆O₂S₂)](CF₃SO₃)·0.6CH₂Cl₂}_n, (I), bis(μ‐1,4‐bis{[5‐(quinolin‐2‐yl)‐1,3,4‐oxadiazol‐2‐yl]sulfanyl}butane)dicopper(I) bis(tetrafluoridoborate)–dichloromethane–methanol (1/1.5/1), [Cu₂(C₂₆H₂₀N₆O₂S₂)₂](BF₄)₂·1.5CH₂Cl₂·CH₃OH, (II), and bis(μ‐1,4‐bis{[5‐(quinolin‐2‐yl)‐1,3,4‐oxadiazol‐2‐yl]sulfanyl}butane)dicopper(I) bis(perchlorate)–dichloromethane–methanol (1/2/1), [Cu₂(C₂₆H₂₀N₆O₂S₂)₂](ClO₄)₂·2CH₂Cl₂·CH₃OH, (III). Under the control of the dumbbell‐shaped CF₃SO₃⁻ anion, complex (I) forms a one‐dimensional chain and neighbouring chains form a spiral double chain. Under the control of the regular tetrahedron‐shaped BF₄⁻ and ClO₄⁻ anions, complexes (II) and (III) have been obtained as bimetallic rings, which further interact viaπ–π interactions to form two‐dimensional networks. The anions play a decisive role in determining the arrangement of these discrete molecular complexes in the solid state.     

A Simple Multistep Conversion of 1,2‐Dihydro‐1,1‐dimethoxynaphthalen‐2‐ones to (3,4‐Dihydro‐3,4‐dioxonaphthalen‐2‐yl)acetates

On irradiation (λ=350 nm) in the presence of 1,1‐dimethoxyethene, naphthalene‐1,2‐dionemonoacetals 1 regioselectively afford 1,1,4,4‐tetramethoxycyclobuta[a]naphthalen‐3‐ones 3 . Sequential deprotection of these bis‐acetals first lead to 1,1‐dimethoxycyclobuta[a]naphthalene‐3,4‐diones 4 and then to cyclobuta[a]naphthalene‐1,3,4‐triones 6 , which, in turn, are converted into (3,4‐dihydro‐3,4‐dioxonaphthalen‐2‐yl)acetates 7 by treatment with SiO₂/MeOH/air.     

Synthesis,Cytotoxicity and Antibacterial Studies of Novel Symmetrically and Nonsymmetrically 4‐(Methoxycarbonyl)benzyl‐Substituted N‐Heterocyclic Carbene–Silver Acetate Complexes

From the reaction of 1H‐imidazole ( 1a ), 4,5‐dichloro‐1H‐imidazole ( 1b ), 1H‐benzimidazole ( 1c ), 1‐methyl‐1H‐imidazole ( 1d ), and 1‐methyl‐1H‐benzimidazole ( 1f ) with methyl 4‐(bromomethyl)benzoate ( 2 ), symmetrically and nonsymmetrically 4‐(methoxycarbonyl)benzyl‐substituted N‐heterocyclic carbene (NHC) precursors, 3a – 3f , were synthesized. These NHC precursors were then reacted with silver(I) acetate (AgOAc) to yield the NHC–silver acetate complexes (acetato‐κO){1,3‐bis[4‐(methoxycarbonyl)benzyl]imidazol‐2‐ylidene}silver ( 4a ), (acetato‐κO){4,5‐dichloro‐1,3‐bis[4‐(methoxycarbonyl)benzyl]‐2,3‐dihydro‐1H‐imidazol‐2‐yl}silver ( 4b ), (acetato‐κO){1,3‐bis[4‐(methoxycarbonyl)benzyl]‐2,3‐dihydro‐1H‐benzimidazol‐2‐yl}silver ( 4c ), (acetato‐κO){1‐[4‐(methoxycarbonyl)benzyl]‐3‐methyl‐2,3‐dihydro‐1H‐imidazol‐2‐yl}silver ( 4d ), (acetato‐κO){4,5‐dichloro‐1‐[4‐(methoxycarbonyl)benzyl]‐3‐methyl‐2,3‐dihydro‐1H‐imidazol‐2‐yl}silver ( 4e ), and (acetato‐κO){1‐[4‐(methoxycarbonyl)benzyl]‐3‐methyl‐2,3‐dihydro‐1H‐benzimidazol‐2‐yl}silver ( 4f ), respectively. The three NHC–AgOAc complexes 4a, 4c , and 4d were characterized by single‐crystal X‐ray diffraction. All compounds studied in this work were preliminarily screened for their antimicrobial activities in vitro against Gram‐positive bacteria Staphylococcus aureus, and Gram‐negative bacteria Escherichia coli using the qualitative disk‐diffusion method. All NHC–AgOAc complexes exhibited weak‐to‐medium antibacterial activity with areas of clearance ranging from 4 to 7 mm at the highest amount used, while the NHC precursors showed significantly lower activity. In addition, NHC–AgOAc complexes 4a and 4b , and 4d – 4f exhibited in preliminary cytotoxicity tests on the human renal‐cancer cell line Caki‐1 medium‐to‐high cytotoxicities with IC₅₀ values ranging from 3.3±0.4 to 68.3±1 μM .     

Novel 5‐Methyl‐2‐[(un)substituted phenyl]‐4‐{4,5‐dihydro‐ 3‐[(un)substituted phenyl]‐5‐(1,2,3,4‐tetrahydroisoquinoline‐2‐yl)pyrazol‐1‐yl}‐oxazole Derivatives: Synthesis and Anticancer Activity

Eleven novel 5‐methyl‐2‐[(un)substituted phenyl]‐4‐{4,5‐dihydro‐3‐[(un)substituted phenyl]‐5‐(1,2,3,4‐tetrahydroisoquinoline‐2‐yl)pyrazol‐1‐yl}‐oxazole derivatives were synthesized and characterized by elemental analysis, ESI‐MS, ¹H NMR and ¹³C NMR. All of the compounds have been screened for their antiproliferative activities against PC‐3 cell (human prostate cancer) and A431 cell (human epidermoid carcinoma cancer) lines in vitro. The results revealed that compounds 4g , 4j and 4k exhibited the strong inhibitory activities against the PC‐3 cell lines (with IC₅₀ values of 2.8±0.11, 3.1±0.10 and 3.0±0.06 μg/mL, respectively).